icosapent ethyl / Generic mfg.  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
icosapent ethyl / Generic mfg.
MITIGATE, NCT04505098: A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

Terminated
4
39600
US
Icosapent ethyl, Vascepa
Kaiser Permanente, Amarin Corporation
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
12/22
12/22
IPE-PREVENTION, NCT04562467: The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk

Completed
4
70
Canada
Icosapent Ethyl 1000 MG Oral Capsule [Vascepa], Vascepa, IPE
Canadian Medical and Surgical Knowledge Translation Research Group, HLS Therapeutics, Inc, Unity Health Toronto, Western University, Canada
Cardiovascular Diseases, Cardiovascular Risk Factor, Triglycerides High, Diabetes Mellitus, Type 2
05/23
05/23
ARTCAP, NCT06280976: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

Recruiting
4
200
US
Statin, atorvastatin, Aspirin tablet, aspirin 81 mg, Nexlizet, bempedoic acid-ezetimibe, LEQVIO, inclisiran, Vascepa, icosapent ethyl, Jardiance, empagliflozin, Colchicine
University of Louisville
Coronary Artery Disease, Atherosclerosis, Heart Attack
01/29
01/29

Download Options